TheraRadar
Data updated: May 26, 2026

FILSUVEZ (birch triterpenes)

First-in-Class Orphan Drug Priority Review Fast Track
Dermatology Approved 2023-12-18

Filsuvez is a topical gel used for wounds in patients with dystrophic and junctional epidermolysis bullosa. It treats both adults and children as young as six months old. This medication is prescribed to help manage the skin wounds that characterize these specific types of the condition.

Source: FDA Label • CHIESI

How FILSUVEZ Works

The specific way this medication works to help heal wounds in patients with epidermolysis bullosa is not currently known. There is no established mechanism of action for how the birch triterpenes in the gel produce their therapeutic effect.

1
Indication
--
Phase 3 Trials
1
Priority Reviews
2
Years on Market

Details

Status
Prescription
First Approved
2023-12-18
Patent Cliff
2039

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
GEL

Companies

Active Ingredient: BIRCH TRITERPENES

FILSUVEZ Approval History

2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2023 to 2023
Dec 2023 ORIGINAL Priority
New Drug · Type 1 - New Molecular Entity

What FILSUVEZ Treats

1 indications

FILSUVEZ is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Epidermolysis Bullosa
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FILSUVEZ FDA Label Details

Indications & Usage

FDA Label (PDF)

FILSUVEZ is indicated for the treatment of Epidermolysis Bullosa.

View full patent landscape →
6 OB patents · 3 families · 140 international docs across 35 countries

FILSUVEZ Patents & Exclusivity

Latest Patent: Jan 2039
Exclusivity: Dec 2030

Patents (6 active)

US11266660 Expires Jan 4, 2039
US12268695 Expires Jan 4, 2039
US11083733 Expires Jan 4, 2039
US9827214 Expires Nov 24, 2030
US9352041 Expires Nov 24, 2030
US8828444 Expires Jun 21, 2026

Exclusivity

NCE Until Dec 2028
ODE-460 Until Dec 2030
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for FILSUVEZ

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2039
  • 6 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.